Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Akebia Therapeutics Q2 Sales $62.472M Beat $47.637M Estimate

Author: Benzinga Newsdesk | August 07, 2025 06:03am
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $62.472 million which beat the analyst consensus estimate of $47.637 million by 31.14 percent. This is a 43.13 percent increase over sales of $43.648 million the same period last year.

Posted In: AKBA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist